Renal. Urologic cancers Flashcards
FA. Protate.
most common nonskin cancer in male
second cause of death in men
.
FA. Protate. 2 risk factors?
advanced age and family history
FA. Protate. initial symptoms? 2
asymptomatic, may present with obstructive urinary symptoms
FA. Protate. symptoms. additional?
Constitutional symptoms
lymphedema (from metastases obstructing lymphatic drainage) and/or black pain (bone mestastases)
FA. Protate. DRE?
palpable nodule or an area of induration.
Early carcinoma is usually not detectable
FA. Protate. Diagnosis. 2
Clinical findings and/or increased PSA (> 10 ng/ml)
FA. Protate. Diagnosis. most accurate test?
transrectal US guided biopsy
FA. Protate. Diagnosis. additional need to do what?
Look for metastases with CT of the abdomen/pelvis
and
a bone scan (metastatic lesions shows an osteoblastic or incr. bone density)
FA. key fact. leading causes of cancer death in men? 4
lung, protate, colorectal, pancreatic
FA. Protate. incr. in PSA can be caused by what other diseases?4
BPH, prostatitis, prostatic trauma, carcinoma
FA. Protate. treatment. older adults with low grade.?
watchful waiting, as many cases are slow to progress.
FA. Protate. treatment. radical prostatectomy assoc with what?
incr. risk for incontinence and/or erectile dysfunction
FA. Protate. treatment. radiation therapy, assoc with what?
incr. risk for radiation proctitis and GI symptoms.
erectile dysfunction posttreatment.
FA. Protate. treatment. PSA for what purpose used?
contraversial for screening
used to follow patient post treatment to evaluate for disease recurrence
FA. Protate. treatment. metastatic disease treatment?
androgen ablation (gonadotropin-releasing hormone agonists, orchiectomy, bicalutamide)
and
chemotherapy
FA. Protate. treatment. metastatic disease treatment.
Radiation therapy bone?
useful to manage bone pain from metastases after androgen ablation
FA. Protate. prevention.
screening guidelines contraversial :)))) THE FUCK
Males should discuss pros and cons of anual DRE and/or PSA starting at 50 y/o.
FA. Protate. prevention. in what patients start earlier than 50 yo?
black males and in those with first-degree relative with prostate cancer
FA. Bladder.
second most common urologic cancer and the most frequent malignant tumor of urinary tract. THE FUCK
.
FA. Bladder. what usually carcinoma?
transitional cell carcinoma (now called urothelial carcinoma)
FA. Bladder. in what age?
most prevalent in 60-70 decade in males
FA. Bladder. risk factors?
smoking, diet rich in meat ant fat, schistosomiasis (squamous cell carcinoma), past treatment of cyclophosphamide, ocupational exposure to anilin dye
FA. Bladder. symtoms.
Gross, painless hematuria
Terminal hematuria (end of voiding) suggests bleeding from bladder
FA. Bladder. other symptoms than most common?
frequency, urgency, dysuria can also be seen.
Most patients are asymptomatic in the early stages
FA. Bladder. diagnosis.
methods?
Sceening - not recommended
UA - hematuria (microscopic or macroscopic)
cystoscopy + biopsy is diagnostic
urine cytology - dysplastic cells
MRI, CT, bone scan - for muscle invasion and metastases
FA. Bladder. diagnosis. which method is diagnostic?
cystoscopy + biopsy
FA. Bladder.
diagnosis. when recommended cysto+ biopsy?
in adults > 35 yo with unexplained hematuria
FA. Bladder. treatment. depends on what?
extent of spread beyond the bladded mucosa
FA. Bladder. treatment. Carcinoma in situ?
intravesicular chemotherapy or transuretheral resection.
FA. Bladder. treatment. superficial cancers?
Complete transuretheral resection or intravesicular chemotherapy with mitomycin C or BCG (TB vaccine)
FA. Bladder. treatment. Large, high grade recurrent lesions.
intravesicular chemotherapy
FA. Bladder. treatment. invasive cancer without metastases.
radical cystectomy or radiation therapy for patients who are deemed poor candidates for radical cystectomy and for those with unresectable local disease.
Nonadjuvant systemic therapy and radiosensitization is often considered.
FA. Bladder. treatment. invasive cancer with distant metastases.
Chemotherapy, immunotherapy, novel targeted agents are considered.
FA. key fact. key step for diagnosis in an adult with unexplained hematuria is cystoscopy to evaluate for bladder cancer.
.
FA. RCC. origin?
Adenocarcinoma from tubular epithelial cells
FA. RCC. spread way?
spread along the renal vein the the IVC and metastasize to other sites (lungs, bone, brain, liver)
FA. RCC. Risk factors?
male, smoking, obesity, acquired cystic kidney disease in ESRD, genetic conditions eg von Hippel Lindau disease.
FA. RCC. symptoms?
gross hematuria, flank pain, scrotal varicoceles, palpable flank mass.
FA. RCC. metastatic disease symtoms?
weight loss, malaise, symptoms according to metastases site